Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05573451 | Comparison of the Accuracy of US, MRI and PET/CT in the Assessment of LNs in Cervical Cancer.(CANNES) | active not recruiting | — | 91 | General University Hospital, PragueOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05656326 | Follow-up After Surgery for Colorectal Cancer(FUTURE-primary) | active not recruiting | — | 200 | Erasmus Medical CenterOTHER |
| 1 |
| Sep 25, 2024 |
| clinicaltrials |
| NCT06612671 | Treatment Outcomes of Retroperitoneal Sarcoma | active not recruiting | — | 150 | Taichung Veterans General HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06612697 | Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone | active not recruiting | — | 262 | Taichung Veterans General HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04571840 | Prostate Imaging Using MRI +/- Contrast Enhancement(PRIME) | active not recruiting | N/A | 500 | University College, LondonOTHER | 15 | Sep 23, 2024 | clinicaltrials |
| NCT05638698 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA) | active not recruiting | Phase 2 | 24 | University of Kansas Medical CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06606912 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients | active not recruiting | — | 4,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03789981 | Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia(Immune-AML) | active not recruiting | — | 75 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 30 | Joseph TuscanoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03154346 | Project Baseline Health Study | active not recruiting | — | 10,000 | Baseline Study LLCINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03454763 | Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors(LUTHREE) | active not recruiting | Phase 2 | 618 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03541083 | Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.(HOVON146ALL) | active not recruiting | Phase 2 | 71 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients(HO155) | active not recruiting | Phase 2 | 140 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04515615 | Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) | active not recruiting | Phase 2 | 52 | Yu jirenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04539496 | A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 402 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04875351 | Breast Cancer Index (BCI) Registry | active not recruiting | — | 3,465 | Biotheranostics, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04970134 | Spanish Study for Molecular Characterization of Thyroid Carcinoma(MOLTHY) | active not recruiting | — | 150 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05139043 | Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors | active not recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05724329 | Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | active not recruiting | Phase 2 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05953181 | Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer(SANO) | active not recruiting | N/A | 776 | Erasmus Medical CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06540261 | The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | active not recruiting | Phase 1 | 65 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06584630 | Molecular Classification of Endometrial Cancer: Impact on Adjuvant Treatment Planning. | active not recruiting | — | 80 | Aristotle University Of ThessalonikiOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06595667 | Fluid Responsiveness in Posterior Fossa Tumor Resection: PPV and CVP Guidance | active not recruiting | N/A | 50 | Chiang Mai UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601985 | Exploring the Effect of Colonic J-pouch in Anorectal Preservation Surgery for Ultra-low Rectal Cancer. | active not recruiting | — | 154 | Shanghai 10th People's HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT06550336 | A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). | active not recruiting | Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT01686126 | Improving the Treatment for Women With Early Stage Cancer of the Uterus(feMMe) | active not recruiting | Phase 2 | 165 | Queensland Centre for Gynaecological CancerOTHER_GOV | 2 | Aug 28, 2024 | clinicaltrials |
| NCT05361902 | A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer(UPRATE) | active not recruiting | N/A | 35 | Erasmus Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02802553 | Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions | active not recruiting | N/A | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | active not recruiting | Phase 3 | 275 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566729 | MRD in High-risk EBC | active not recruiting | — | 125 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01464606 | International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry | active not recruiting | N/A | 156 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02754297 | Personalized PRRT of Neuroendocrine Tumors(P-PRRT) | active not recruiting | Phase 2 | 275 | CHU de Quebec-Universite LavalOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03360994 | WATChmAN Virtual Testicular Cancer Clinic | active not recruiting | N/A | 144 | University Health Network, TorontoOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04049513 | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)(ENABLE-1) | active not recruiting | Phase 1 | 30 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04685070 | Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 56 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06549920 | Danish Breast Cancer Group Internal Mammary Node Study(DBCG IMN) | active not recruiting | N/A | 7,630 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Aug 12, 2024 | clinicaltrials |
| NCT05015010 | Alectinib in Neo-adjuvant Treatment of Stage III NSCLC(ALNEO) | active not recruiting | Phase 2 | 33 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06547385 | Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | active not recruiting | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06547944 | Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(ZGR in TN CLL) | active not recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06542731 | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 42 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04545710 | Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance | active not recruiting | Phase 2 | 18 | University of California, San DiegoOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06531447 | First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients | active not recruiting | Phase 2 | 200 | The National Center of Oncology, AzerbaijanOTHER_GOV | 1 | Aug 1, 2024 | clinicaltrials |
| NCT00048958 | Cytogenetic Studies in Acute Leukemia and Multiple Myeloma | active not recruiting | — | 9,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 25, 2024source: clinicaltrials